Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Blau

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioningJochen Casper, Daniel Wolff, Wolfgang Knauf, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Bone Marrow Transplantation|February 21, 2007
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myelomaM Schmidt-Hieber, I W Blau, R Trenschel, et al.
Nature Communications|May 24, 2012
Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injuryMatthew Campbell, Finnian Hanrahan, Oliviero L Gobbo, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.
Haematologica|August 30, 2023
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry studyJan Frederic Weller, Claudia Lengerke, Jürgen Finke, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioningJochen Casper, Daniel Wolff, Wolfgang Knauf, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Bone Marrow Transplantation|February 21, 2007
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myelomaM Schmidt-Hieber, I W Blau, R Trenschel, et al.
Nature Communications|May 24, 2012
Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injuryMatthew Campbell, Finnian Hanrahan, Oliviero L Gobbo, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.
Haematologica|August 30, 2023
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry studyJan Frederic Weller, Claudia Lengerke, Jürgen Finke, et al.
Pageof 13